Can an arthritis drug tame deadly dengue inflammation?
NCT ID NCT05611710
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether anakinra, an anti-inflammatory drug, can help people with severe dengue who have dangerously high inflammation. About 160 adults and children will receive either anakinra or a placebo for four days. The goal is to see if anakinra reduces organ failure and improves recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anakinra (an anti-inflammatory drug given intravenously)
- What this could lead to
- If it works, this could offer a way to prevent organ failure in severe dengue patients with dangerous inflammation.
- What could go wrong
- This is a mid-stage trial with only 160 participants, so results may not apply to all dengue patients. Anakinra may not improve outcomes and could have side effects like increased infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAKINRA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital for Tropical Diseases
Ho Chi Minh City, Vietnam
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists deliberately infect volunteers with dengue to unlock immune secrets
- Could a common steroid tame deadly dengue?
- Could papaya leaves help fight dengue? new trial tests the idea
- Could a Mitochondria-Boosting supplement beat multivitamins for preventing colds?
- Dengue danger linked to leaky gut? new study investigates
- Exercise program aims to restore strength after dengue and chikungunya